AtaCor Medical

What AtaCor Medical does

AtaCor Medical, Inc. is a privately held medical device company headquartered in San Clemente, California, developing extravascular implantable cardioverter defibrillator (EV-ICD) technology for the treatment of life-threatening ventricular tachyarrhythmias. Its core product is the EV-ICD Lead System, centered on the proprietary Atala lead and a parasternal delivery system that implants the lead outside the heart and vasculature. The system is designed to deliver defibrillation, antitachycardia pacing (ATP), and shock therapies without transvenous access, eliminating risks such as vascular injury, lead fractures, tricuspid valve damage, and infections associated with conventional transvenous ICDs. Compatibility with commercially available transvenous ICD generators in either lateral or pectoral pocket placements is a deliberate architectural choice to lower adoption friction.

AtaCor is pre-commercial and pre-revenue: its products are explicitly stated to be under development exclusively for investigational use and not approved for sale in any geography. The company is currently running the ASCEND EV Clinical Study in the United States (first permanent implantations in March 2025) with a larger ALARION EV pivotal trial planned for 2026 in collaboration with Abbott. The planned go-to-market model combines direct sales to hospitals and cardiac electrophysiology centers with a co-development and distribution arrangement with Abbott, under which AtaCor's Atala lead is paired with Abbott's ICD system and commercialized through Abbott's established cardiac rhythm management channel.

Leadership is drawn from the Cameron Health, Boston Scientific, Guidant, and Zoll lineage that originally developed the subcutaneous ICD, including CEO Rick Sanghera (70+ CRM patents) and co-founder/VP Regulatory Alan Marcovecchio. Scientific Advisory Board members include principal investigators from the PRAETORIAN trial (Reinoud Knops, Amsterdam UMC) and Mount Sinai's cardiac arrhythmia program (Vivek Reddy). Through October 2025, the company has raised approximately $137 million across four funding rounds, with a $28M Series C in April 2024 led by Arboretum Ventures and a $75M financing in October 2025 earmarked for the FDA pivotal study.

Name

AtaCor Medical

Legal name

AtaCor Medical, Inc.

Website

https://atacor.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

AtaCor Medical is a private medical device company developing an extravascular implantable cardioverter defibrillator lead system that delivers defibrillation and pacing therapies without entering the heart or vasculature, targeting hospitals and cardiac electrophysiology centers.

Ownership category

akta.pro rank

Product category

Cardiac Rhythm Management Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)

akta.pro secondary industry

Electrophysiology (Heart Rhythm) (HLAKABAC)

Keywords

• Cardiac rhythm management
• Extravascular ICD leads
• Implantable defibrillators
• Cardiac medical devices
• Electrophysiology devices

Headquarters

HQ city

San Clemente

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Extravascular ICD Lead System: AtaCor Medical generates revenue through the sale of its EV-ICD Lead System (Atala lead and delivery system) to hospitals and cardiac rhythm management centers. The system is designed to be compatible with commercially-available transvenous ICDs, creating a consumable/impantable device revenue model. The company is currently in clinical development stage with products under investigational use only.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

AtaCor Medical develops and clinically investigates extravascular implantable cardioverter defibrillator (EV-ICD) lead systems designed to deliver defibrillation, antitachycardia pacing (ATP), and shock therapies without placing hardware inside the heart or vasculature. The company's flagship offering, the Atala EV-ICD Lead System, uses a streamlined parasternal delivery approach and is designed for compatibility with commercially-available transvenous ICDs. The products are currently for investigational use only and are not approved for sale in any geography.

Product overview

AtaCor Medical offers a unified extravascular cardiac rhythm management solution centered on its EV-ICD Lead System, which combines the proprietary Atala extravascular lead with a streamlined parasternal delivery system and compatibility with commercially-available transvenous ICDs. The system delivers defibrillation, antitachycardia pacing (ATP), and shock therapies without placing hardware inside the heart or vasculature. The company is also advancing a separate investigational Parasternal EV-ICD System in collaboration with Abbott, planned for a pivotal clinical trial in 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Atala: Investigational extravascular ICD lead designed to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies without hardware placed in the heart or vasculature
• EV-ICD Lead System
• Parasternal EV-ICD System

Products and services

• EV-ICD Lead System AtaCor's flagship extravascular implantable cardioverter defibrillator (EV-ICD) lead system designed to deliver reliable sensing, antitachycardia pacing (ATP), and shock therapies to treat life-threatening ventricular tachyarrhythmias without entering the heart or vascular system. Features the Atala lead implanted via a streamlined parasternal approach, compatible with commercially-available transvenous ICDs for both lateral and pectoral pulse generator pocket placement. Targeted at hospitals and cardiac electrophysiology centers.
• Parasternal EV-ICD System An investigational next-generation extravascular ICD system developed through strategic collaboration with Abbott, pairing AtaCor's Atala lead with Abbott's ICD system. A pivotal clinical trial (ALARION EV Study) is planned for 2026 to evaluate the combined parasternal EV-ICD system. Targeted at cardiac rhythm management hospitals and electrophysiology centers.

Quantifiable outcome

• First permanent implantation of EV-ICD Lead System completed March 2025 as part of ASCEND EV Clinical Study
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• AbbottcoreStrategic or Co-development Partner · 13 January 2026Abbott and AtaCor Medical announced collaboration to advance a next-generation extravascular implantable cardioverter defibrillator (EV-ICD) system. AtaCor's investigational Atala lead will be paired with Abbott's ICD system. A pivotal clinical trial (ALARION EV Study) is planned for 2026 to evaluate the investigational parasternal EV-ICD system.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Boston Scientific: Acquired Cameron Health and markets the EMBLEM subcutaneous ICD (S-ICD), the leading extravascular defibrillator today. Direct overlap with AtaCor in extravascular ICD therapy and a likely fast-follower in the EV-ICD-with-ATP category.
• Medtronic: Global leader in CRM with deep transvenous ICD, pacemaker, and CRT-D franchises. Competes in the same hospital call point and has active extravascular/subleadless research that could rival AtaCor's Atala platform.
• BIOTRONIK: Privately held German CRM and electrophysiology device maker with a full line of ICDs and pacemakers. Competes in the same hospital accounts for implantable cardiac devices, including extravascular/subcutaneous programs.
• MicroPort Scientific: Global medical device conglomerate with an active CRM franchise (including ICDs) following its acquisition of LivaNova's CRM business. Competes in the broader implantable CRM market alongside AtaCor's target accounts.

Direct peers

• Abbott: Top-3 CRM incumbent and AtaCor's strategic partner on the ALARION EV Study. Markets its own ICD portfolio and will pair AtaCor's Atala lead with its generator, making Abbott simultaneously collaborator and competitor.
• Cameron Health (historical): Developer of the original S-ICD, founded by many of the same engineers now at AtaCor. Acquired by Boston Scientific in 2012 for approximately $1.4B; serves as the closest analog to AtaCor's positioning and exit trajectory.

Emerging players

• EBR Systems: Developer of leadless pacing technology (WiSE-CRT) for cardiac resynchronization therapy. Comparable as a venture-backed CRM device innovator targeting extravascular or novel-delivery cardiac stimulation approaches.
• Imricor Medical Systems: Focused on MRI-guided cardiac ablation and electrophysiology devices. Comparable as a small-cap, clinical-stage CRM innovator selling into the same EP hospital call point.
• Cala Health: Venture-backed bioelectronic therapy company developing wearable neuromodulation devices for cardiac and neurological conditions. Adjacent peer as a venture-stage electrotherapy innovator in similar reimbursement pathways.
• Cardiac Insight: Developer of wearable ECG/arrhythmia diagnostic devices targeting the same cardiology electrophysiology call points. Adjacent peer as a small-cap cardiac device company selling into hospital EP labs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/atacor-medical-inc-
• Xx.com/atacormedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AtaCor Medical